written on 19.06.2014

Pharmacyclic’s Imbruvica Beats GSK’s Arzerra in Elderly CLL Patients


As the American Society of Clinical Oncology (ASCO) meeting entered day two, coffee-sipping attendees perked to a first-in-the-morning discussion of the phase III data with Pharmacyclics Inc.’s ibrutinib (branded Imbruvica) in relapsed chronic lymphocytic leukemia (CLL), the first time an oral drug has yielded survival improvement over standard therapy. CLL is usually treated with chemo-immunotherapy, […]